A 36-gene signature predicts clinical progression in a subgroup of ERG-positive prostate cancers

European Urology

Volumn 64, Issue 6, 2013, Pages 941-950

  Gasi Tandefelt, Delila ^a   Boormans, Joost L ^a   Van Der Korput, Hetty A ^a   Jenster, Guido W ^a   Trapman, Jan ^a  

^a JOSEPHINE NEFKENS INSTITUTE   (Netherlands)

Author keywords

ETS; Expression arrays; Predictor; Prostate cancer; TMPRSS2 ERG

Indexed keywords

ADIPOCYTE ENHANCER BINDING PROTEIN 1; ALPHA 1 TYPE VIII COLLAGEN; ALPHA 2 MACROGLOBULIN; CADHERIN; CADHERIN 11; CANCER GROWTH FACTOR BETA; CARBOXYPEPTIDASE X MEMBER 2; CARTILAGE OLIGOMERIC MATRIX PROTEIN; CATHEPSIN K; COMPLEMENT COMPONENT C1R; FIBULIN 5; GROWTH FACTOR; INHIBIN; INHIBIN BETA A; LATENT TRANSFORMING GROWTH FACTOR BETA BINDING PROTEIN 2; MONOOXYGENASE DBH LIKE 1; OB CADHERIN; PREGNANCY ASSOCIATED ALPHA2 GLYCOPROTEIN; PROSTATE SPECIFIC ANTIGEN; SECRETED FRIZZLED RELATED PROTEIN 2; SPINDLE PROTEIN CHICA; SULFATASE 1; THROMBOSPONDIN 2; TRANSCRIPTION FACTOR ERG; TRANSMEMBRANE PROTEASE SERINE 2; TRANSMEMBRANE PROTEIN 119; TUMOR PROTEIN; TYPE X COLLAGEN ALPHA 1; UNCLASSIFIED DRUG; VERSICAN;

AVIAN ERYTHROBLASTOSIS ONCOVIRUS; BONE REMODELING; CANCER GROWTH; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CANCER SURGERY; CELL ADHESION; FOLLOW UP; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE; OSTEOBLAST; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; REVIEW;

ETS; EXPRESSION ARRAYS; PREDICTOR; PROSTATE CANCER; TMPRSS2-ERG;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PROGNOSIS; PROSTATIC NEOPLASMS; TRANS-ACTIVATORS; TRANSCRIPTOME;

EID: 84887407798     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.02.039     Document Type: Article

References (28)

1. R. Siegel, D. Naishadham, and A. Jemal Cancer Statistics, 2012 CA Cancer J Clin 62 2012 10 29
2. J. Lapointe, C. Li, and J.P. Higgins Gene expression profiling identifies clinically relevant subtypes of prostate cancer Proc Natl Acad Sci U S A 101 2004 811 816
3. K.L. Penney, J.A. Sinnott, and K. Fall mRNA expression signature of Gleason grade predicts lethal prostate cancer J Clin Oncol 29 2011 2391 2396
4. E.K. Markert, H. Mizuno, A. Vazquez, and A.J. Levine Molecular classification of prostate cancer using curated expression signatures Proc Natl Acad Sci U S A 108 2011 21276 21281
5. C.S. Grasso, Y. Wu, and D.R. Robinson The mutational landscape of lethal castration-resistant prostate cancer Nature 487 2012 239 243
6. C.E. Barbieri, S.C. Baca, and M.S. Lawrence Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer Nat Genet 44 2012 685 689
7. S.A. Tomlins, D.R. Rhodes, and S. Perner Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer Science 310 2005 644 648
8. K.G. Hermans, R. van Marion, H. van Dekken, G. Jenster, W.M. van Weerden, and J. Trapman TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer Cancer Res 66 2006 10658 10663
9. N. Cerveira, F.R. Ribeiro, and A. Peixoto TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions Neoplasia 8 2006 826 832
10. J. Clark, G. Attard, and S. Jhavar Complex patterns of ETS gene alteration arise during cancer development in the human prostate Oncogene 27 2008 1993 2003
11. F. Demichelis, K. Fall, and S. Perner TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort Oncogene 26 2007 4596 4599
12. L.M. FitzGerald, I. Agalliu, and K. Johnson Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer BMC Cancer 8 2008 230
13. K.G. Hermans, J.L. Boormans, and D. Gasi Overexpression of prostate-specific TMPRSS2 (exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer Clin Cancer Res 15 2009 6398 6403
14. Y. Zong, L. Xin, A.S. Goldstein, D.A. Lawson, M.A. Teitell, and O.N. Witte ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells Proc Natl Acad Sci U S A 106 2009 12465 12470
15. O. Klezovitch, M. Risk, and I. Coleman A causal role for ERG in neoplastic transformation of prostate epithelium Proc Natl Acad Sci U S A 105 2008 2105 2110
16. B.S. Carver, J. Tran, and A. Gopalan Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate Nat Genet 41 2009 619 624
17. J.C. King, J. Xu, and J. Wonqvipat Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis Nat Genet 41 2009 524 526
18. S.A. Tomlins, B. Laxman, and S. Varambally Role of the TMPRSS2-ERG gene fusion in prostate cancer Neoplasia 10 2008 177 188
19. S. Jhavar, D. Brewer, and S. Edwards Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer BJU Int 103 2008 1256 1269
20. J.C. Brase, M. Johannes, and H. Mannsperger TMPRSS2-ERG specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling BMC Cancer 11 2011 507
21. B.S. Taylor, N. Schultz, and H. Hieronymus Integrative genomic profiling of human prostate cancer Cancer Cell 18 2010 11 22
22. H.V. Heemers, L.J. Schmidt, and Z. Sun Identification of a clinically relevant androgen-dependant gene signature in prostate cancer Cancer Res 71 2011 1978 1988
23. J. Cuzick, G.P. Swanson, and G. Fisher Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study Lancet Oncol 12 2011 245 255
24. S.A. Tomlins, B. Laxman, and S.M. Dhanasekaran Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer Nature 448 2007 595 599
25. J. Lapointe, C. Li, and C.P. Giacomini Genomic profiling reveals alternative genetic pathways of prostate tumorigenesis Cancer Res 67 2007 8504 8510
26. A. Toubaji, R. Albadine, and A.K. Meeker Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas Mod Pathol 24 2011 1511 1520
27. H. Kim, J. Watkinson, V. Varadan, and D. Anastassiou Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1 BMC Med Genomics 3 2010 51
28. P. Wikström, P. Stattin, I. Franck-Lissbrant, J.E. Damber, and A. Bergh Transforming growth factor beta is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer Prostate 37 1998 19 29